EGFR and non-small cell lung carcinoma: It has been used for the treatment of non-small-cell lung cancer (NSCLC), which is refractory to tyrosine kinase inhibitors (TKIs), especially for a subtype of NSCLC with EGFR mutations [13,33,60].